1. | asheymommy | |
2. | dynamichealthsol | |
3. | badaleyes | |
4. | franciscaguila78 | |
5. | marz11 |
1. | asheymommy | |
2. | dynamichealthsol | |
3. | badaleyes | |
4. | franciscaguila78 | |
5. | marz11 |
1. | dynamichealthsol 02/02/2018 Beats EPS estimates by $0.04. |
2. | badaleyes 02/02/2018 Big news - Sees FY18 revs $41.2-42.7 bln vs $41.10 bln |
3. | dynamichealthsol 01/03/2018 er details |
4. | marz11 04/10/2018 Merck monotherapy met primary endpoint in phase 3 keynote-042 study, significantly improving OS as first-line… |
5. | asheymommy 01/26/2018 today > $MRK - CHMP gave positive opinions for three medicines to treat type 2 diabetes: Segluromet (ertugliflozin / metform… |
6. | asheymommy 03/01/2018 News |
7. | asheymommy 02/15/2018 AstraZeneca and Merck |
8. | asheymommy 01/26/2018 News out. GL |
9. | dynamichealthsol 03/23/2018 Announced multiple receptor tyrosine kinase inhibitor LENVIMA has been approved in Japan for unresectable hep… |
10. | badaleyes 02/05/2018 Now is the time to get out |